Peter Dudek

Peter Dudek, Ph.D., has more than 13 years of experience in the life sciences industry spanning research, company building, as well as corporate and traditional venture capital, across a broad range of therapeutic areas and modalities. He currently serves as President and Managing Partner of Merck’s MRL Ventures Fund and is responsible for its investments in Carisma, HotSpot, Kymera, Imago, Xilio, and Caraway Therapeutics. Prior to MRLV, he was a Principal with Wellington Partners, a Munich and London-based European venture fund, and was involved in investments across a broad range of life science companies including Middle Peak Medical, Atopix, Optinose, Prosonix, iOmx, Imevax, Oxagen, and Vasopharm. He has also held roles at Entrepreneurs Fund and at the corporate venture arm of Novartis. Peter holds a BS with Honors from the University of British Columbia, obtained his Ph.D. from the University of Geneva, and was a postdoctoral fellow at the University of Oxford.